BioMarin Pharmaceutical Inc. (BMRN)

BioMarin Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	972.15	755.13	724.53	587.28	649.16	437.45
Short-Term Investments	252.2	318.68	567.01	426.6	416.23	316.36
Cash & Short-Term Investments	1,224	1,074	1,292	1,014	1,065	753.81
Cash Growth	4.56%	-16.86%	27.39%	-4.83%	41.33%	-30.48%
Accounts Receivable	691.23	633.7	461.32	373.4	448.35	377.4
Receivables	691.23	633.7	461.32	373.4	448.35	377.4
Inventory	1,184	1,107	894.08	776.67	698.55	680.28
Other Current Assets	160.43	141.39	104.52	110.44	129.93	130.66
Total Current Assets	3,260	2,956	2,751	2,274	2,342	1,942
Property, Plant & Equipment	1,053	1,112	1,114	1,082	1,090	1,070
Long-Term Investments	563.78	622.44	370.34	524.29	295.97	418.18
Goodwill	196.2	196.2	196.2	196.2	196.2	197.04
Other Intangible Assets	265.53	325.3	338.57	388.65	417.27	456.58
Long-Term Deferred Tax Assets	1,545	1,546	1,505	1,450	1,432	549.42
Other Long-Term Assets	184.07	83.56	98.78	89.2	74.63	56.38
Total Assets	7,067	6,842	6,375	6,005	5,848	4,690
Accounts Payable	257.41	315.51	231.24	199.68	191.43	240.98
Accrued Expenses	268.84	311.55	293.53	267.65	257.27	288.82
Current Portion of Long-Term Debt	494.84	493.88	-	-	-	361.88
Current Portion of Leases	10.69	8.78	10.38	10.46	11.75	10.7
Current Income Taxes Payable	18.86	2.65	16.21	1.21	9.66	3.2
Current Unearned Revenue	1.91	4.62	0.71	6.96	0.15	13.04
Other Current Liabilities	14.79	40.04	36.81	60.54	22.29	13.89
Total Current Liabilities	1,067	1,177	588.88	546.5	492.55	932.5
Long-Term Debt	594.12	593.1	1,083	1,079	1,075	486.24
Long-Term Leases	-	38.12	26.51	33.84	44.49	50.8
Other Long-Term Liabilities	119.37	81.81	73.5	79.69	129.84	98.12
Total Liabilities	1,781	1,890	1,772	1,739	1,742	1,568
Common Stock	0.19	0.19	0.19	0.18	0.18	0.18
Additional Paid-In Capital	5,697	5,612	5,405	5,192	4,993	4,833
Retained Earnings	-425.72	-621.55	-789.2	-930.76	-861.61	-1,721
Comprensive Income & Other	15.13	-38.65	-12.73	4.74	-25.98	10.2
Shareholders' Equity	5,286	4,952	4,603	4,266	4,106	3,122
Total Liabilities & Equity	7,067	6,842	6,375	6,005	5,848	4,690
Total Debt	1,100	1,134	1,120	1,123	1,131	909.62
Net Cash (Debt)	124.71	-60.07	171.63	-109.51	-66	-155.81
Net Cash Growth	60.56%	-	-	-	-	-
Net Cash Per Share	0.64	-0.31	0.91	-0.60	-0.34	-0.87
Filing Date Shares Outstanding	190.38	188.68	186.53	184.03	181.83	179.93
Total Common Shares Outstanding	190.36	188.6	186.25	183.91	181.74	179.84
Working Capital	2,192	1,779	2,163	1,728	1,850	1,010
Book Value Per Share	27.77	26.25	24.71	23.19	22.59	17.36
Tangible Book Value	4,825	4,430	4,068	3,681	3,493	2,469
Tangible Book Value Per Share	25.35	23.49	21.84	20.01	19.22	13.73
Land	-	90.78	90.79	90.42	90.42	90.42
Buildings	-	860.81	819.1	774.92	761.56	725.91
Machinery	-	796.61	736.25	688.54	644.4	573.07
Construction In Progress	-	100.01	143.38	136.74	109.14	111.9
Leasehold Improvements	-	58.23	59.53	55.28	55.13	51.32

Source: S&P Capital IQ. Standard template. Financial Sources.